Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. - Wikidata - wikimedia - TriplyDB

Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.

Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.

http://www.wikidata.org/entity/Q33384898

about

Temozolomide for high grade glioma Recent advances in the molecular understanding of glioblastoma Advances in the treatment of newly diagnosed glioblastoma Recent advancements in multimodality treatment of gliomas Controversies in the adjuvant therapy of high-grade gliomas.Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas.Ependymoma stem cells are highly sensitive to temozolomide in vitro and in orthotopic models.Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Central nervous system cancers Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma Medical therapy of gliomas.Surgical resection of malignant gliomas-role in optimizing patient outcome.Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).The use and effectiveness of temozolomide in children with central nervous system tumours: a survey from the Canadian Paediatric Brain Tumour Consortium Temozolomide in malignant glioma Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group.A phase I study of high-dose calcitriol in combination with temozolomide for patients with metastatic melanoma.Towards personalized therapy for patients with glioblastoma.Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.Overcoming the challenges in the effective delivery of chemotherapies to CNS solid tumors.Do glioma patients derive any therapeutic benefit from taking a higher cumulative dose of temozolomide regimens?: a meta-analysis.MGMT testing allows for personalised therapy in the temozolomide era.MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR Dose-dense temozolomide: is it still promising?Radiotherapy and temozolomide for anaplastic astrocytic gliomas.The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.Extended adjuvant temozolomide with cis-retinoic acid for adult glioblastoma.Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed Glioblastoma Patients? A Multi-center, Randomized, Parallel, Open-label, Phase II Clinical Trial.MRI perfusion in determining pseudoprogression in patients with glioblastoma.Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients Update on emerging drugs for cancer cachexia.Treatment of pituitary neoplasms with temozolomide: a review.Current and emerging molecular targets in glioma.Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis.Temozolomide in aggressive pituitary adenomas and carcinomas.Metronomic chemotherapy for cancer treatment: a decade of clinical studies.

P2860

Q24197645-41D3DCC9-873A-4EBF-B999-DD4E95881807 Q24632928-0F4F2A30-348B-4300-9B40-1FB83F6A388E Q26773514-43371036-2A99-4170-8F79-A6245458DD27 Q27001724-99F6D83F-FD84-4F8D-AF37-CC647D86F24B Q33394265-AF7C6C66-E941-4444-98FE-562858D9B6BC Q33636469-3C755D6C-C95C-4E9D-8686-E6521BABBB13 Q33769095-5EC21D0E-DB70-4C5C-9054-C0732AD04CE3 Q33894470-5527FDF9-098A-43F0-AC21-BDB6F2AE4447 Q33916064-C6358354-A15E-4231-A4A5-751EFFC74F8F Q34014740-DFCA3F17-CABB-4DE7-8CDD-523B65309DFE Q34062033-4D2CB17B-F5BC-4D8E-99ED-6F6DCB62381F Q34218761-712AC76A-23A6-45B0-B069-8E520DCC0596 Q34324963-E1B34D4B-5EB8-4C0C-856F-BA741048C184 Q34478948-4112C026-6E94-466A-A920-6F9E0D4211E2 Q34541456-8D6BFCD5-E73E-4B2C-9F70-C2B36CEA699F Q34623633-F5C385C5-6766-4F24-9E6B-B600E1CF2184 Q34722440-CB0F9F1A-3BB1-44A9-BB6A-29D64FA799EF Q34809620-868C6AE8-7853-40AA-BA5E-0E2EBE665235 Q34978252-40808EF7-DD8E-4219-9A8D-83DA367A612E Q35419401-554B99EF-D6AF-42EB-911C-94B715790055 Q35602796-73F16128-51DD-4DEF-BF2C-9E557A06E645 Q35638372-9FC1A651-4200-49D3-930F-565C0C3820EA Q35827916-6C5802A6-6AA3-49A1-86B6-E0928EF20C28 Q35850389-16CE5A9F-09D4-4903-82FF-340CA464A5C6 Q35943654-D9655DFC-4DDC-436B-84DD-5E333EB159D8 Q36163603-6DD32CC4-19F1-4210-9C3B-6F027BADCFBF Q36299167-85ACA120-DF4E-43BE-8DBE-0BB696C837F6 Q36416218-64500D51-FE8D-43A5-9594-07C8A9FE8ECC Q36515232-6EC28B4F-0D3A-4152-ABA9-4FB41C2D61B7 Q36531871-A6A4391D-06B5-4BB3-99BC-B18054FF9173 Q36585386-46E102E2-F820-4DC7-B637-C79EDB86C1EF Q36866006-77008CE4-A3DC-494D-BA53-2F4C467D166E Q37236004-3182D91F-AB9B-4E0B-B922-0DF38E22C75D Q37418411-4564934B-0428-4A53-9DEB-4B439FE83960 Q37622253-4FA5C853-85D9-4094-85C3-BA64E546638C Q37789267-7FC91488-6662-481C-B65A-40E350FC6C2B Q37809861-A524DB65-42B6-40A7-A68C-7573A583418D Q37869402-EE404B33-C2B3-44F8-9360-F8C494BF1C1B Q38010032-C557ABBD-552B-4FEE-8B0D-5B931E49CE3D Q38087885-96A0068B-6B59-49F0-BB50-3608D5670D92

P2860

Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.

http://www.wikidata.org/entity/Q33384898

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Randomized phase II trial of c ...... newly diagnosed glioblastoma.

@ast

Randomized phase II trial of c ...... newly diagnosed glioblastoma.

@en

type

label

Randomized phase II trial of c ...... newly diagnosed glioblastoma.

@ast

Randomized phase II trial of c ...... newly diagnosed glioblastoma.

@en

prefLabel

Randomized phase II trial of c ...... newly diagnosed glioblastoma.

@ast

Randomized phase II trial of c ...... newly diagnosed glioblastoma.

@en

P1433

Q33384898-06668E60-B94C-407B-B4AA-5EC03BC14790

P1476

Q33384898-756112F3-8B99-4CD7-809F-B19701B8C10C

P2093

Q33384898-208D193B-1C6B-4149-9FD5-61F8A4830C78

Q33384898-453D5200-D9EF-4E5D-81E5-0F394A7E4BEB

Q33384898-4B02D515-FE59-4F62-A8F9-CFE2B0357068

Q33384898-92C80279-0DC4-4BA3-9FEE-B7C0379D1D18

Q33384898-A4D2B301-5DCD-44DC-8A66-949465C24B0B

Q33384898-C1654D85-5CC6-45EB-99A6-37237AA29669

Q33384898-C343F4A2-5B52-415C-B4C2-32BD6F4EFC34

Q33384898-E38FD666-3B9E-4F1C-837A-84E4ED23C154

P2860

Q33384898-08A00DE5-8A10-4BA3-AC5E-3353ED6F256E

Q33384898-33BDD6CF-9C8C-4ABE-8CF4-FF52C8F80E5F

Q33384898-3B769D01-5827-46CB-889F-B4902A62ADD7

Q33384898-3C63B18E-DBEC-45A5-937D-62DCD6C889A1

Q33384898-3E43ED60-550E-416F-AE1C-5120D2A94502

Q33384898-4A26543E-9C36-484D-91FE-D86173C24CB2

Q33384898-4BD6322A-A830-489F-88E5-923CC09D4CF0

Q33384898-5AC2346E-BE51-434D-AF96-2CAADBE98FF7

Q33384898-609A1342-A7D0-49E4-ABAF-81B1F62E1BE7

Q33384898-637C82EB-DE93-4CE2-8815-EFCA96954CC1

P304

Q33384898-BB30FB67-0819-4741-935E-B99BAB5C5E4B

P31

Q33384898-EE81DDB2-00F8-41DF-B114-FF5BDF4F00DB

P356

Q33384898-C6636141-AF83-4453-B1E3-8996FF7DCE79

P407

Q33384898-3C73B819-4B12-4E4F-9ECD-7FFAA0B555E5

P433

Q33384898-441C9581-45F8-4132-B4A1-DD76E320D7EE

P478

Q33384898-F00F083D-4193-46FA-A448-65DEA98DEA4E

P50

Q33384898-D2A36075-335D-4299-99A6-60804396C1C0

Q33384898-EE914975-D138-49D2-949A-A229980D12CC

Q33384898-F86214EC-5F5D-4CF8-8A3C-78B11494A11A

P577

Q33384898-8E329130-BBA1-4865-A153-FCD7FC2F7DCA

P698

Q33384898-14B3332D-E8B0-40DF-8918-F168E8DCD8DA

P921

Q33384898-8AAC7760-CA13-4A1C-8E4B-802EA6CEB891

Q33384898-B255FF7D-45CF-4EF6-B0EF-5C53CF313A6E

P932

Q33384898-288E796E-A3D0-44EA-8BD3-B26A28ECC4D7

P356

JCO.2008.20.7944

P1433

Journal of Clinical Oncology

P1476

Randomized phase II trial of c ...... newly diagnosed glioblastoma.

@en

P2093

Adília Hormigo

http://www.w3.org/2001/XMLSchema#string

Andrew B Lassman

http://www.w3.org/2001/XMLSchema#string

Fabio M Iwamoto

http://www.w3.org/2001/XMLSchema#string

Jennifer L Clarke

http://www.w3.org/2001/XMLSchema#string

Joohee Sul

http://www.w3.org/2001/XMLSchema#string

Katherine Panageas

http://www.w3.org/2001/XMLSchema#string

Lauren E Abrey

http://www.w3.org/2001/XMLSchema#string

Sasan Karimi

http://www.w3.org/2001/XMLSchema#string

P2860

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

A phase II study of extended low-dose temozolomide in recurrent malignant gliomas

Study of retinoic acid effect upon retinoic acid receptors beta (RAR-beta) in C6 cultured glioma cells

Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

Phase I trial of temozolomide using an extended continuous oral schedule.

Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.

Inhibition of angiogenesis by non-toxic doses of temozolomide.

The anti-angiogenic basis of metronomic chemotherapy.

P304

3861-3867

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.20.7944

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Lisa M DeAngelis

Igor T Gavrilovic

P577

2009-06-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19506159

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

chemoradiotherapy

P932

2727290

http://www.w3.org/2001/XMLSchema#string